Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insight Molecular Diagnostics Inc.'s SEC filings document a molecular diagnostics issuer developing donor-derived cell-free DNA assays for transplant monitoring. Current reports and proxy materials cover operating results, GraftAssure product disclosures, regulatory and clinical-development updates, investor-presentation materials, and capital-structure matters tied to financing and equity compensation.
Its filings also describe governance subjects including shareholder voting provisions, bylaws, board and executive compensation matters, equity incentive plan awards, and material agreements for specimen collection services related to GraftAssureCore testing.
Insight Molecular Diagnostics reporting person Josh Riggs, who is listed as CEO and President and a director, acquired an option to purchase 400,000 shares of common stock on 09/28/2025. The option has an exercise price of $3.33 per share and an expiration date of 09/28/2035. The filing shows the reporting person directly beneficially owns the 400,000 option shares following the transaction. Vesting: 33 1/3% becomes exercisable after one year of continuous service from the grant date, with the remainder vesting in 24 equal monthly installments thereafter, subject to continued service. The Form 4 is signed by Josh Riggs on 09/30/2025.
Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.
Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.